TARSUS PHARMACEUTICALS

Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease

05 Aug 2022 05:30:00 By Nasdaq GlobeNewswire

Tarsus to Present at the Jefferies 2022 Healthcare Conference

27 May 2022 06:00:00 By Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements

10 May 2022 13:05:01 By Nasdaq GlobeNewswire

Tarsus to Present at Bank of America 2022 Healthcare Conference

06 May 2022 06:00:00 By Nasdaq GlobeNewswire

Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting

05 May 2022 05:30:01 By Nasdaq GlobeNewswire

Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock

03 May 2022 03:58:47 By Nasdaq GlobeNewswire

Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock

02 May 2022 04:01:00 By Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year

02 May 2022 04:00:00 By Nasdaq GlobeNewswire

Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis

29 Apr 2022 18:23:30 By Nasdaq GlobeNewswire

Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting

26 Apr 2022 05:30:01 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements

14 Mar 2022 13:05:00 By Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

09 Mar 2022 14:00:00 By Nasdaq GlobeNewswire

Tarsus to Host Eye Care Leaders Webcast on Unmet Needs in Demodex Blepharitis and Potential of TP-03

02 Feb 2022 13:30:00 By Nasdaq GlobeNewswire

Tarsus Completes Enrollment for the Pivotal Phase 3 Saturn-2 Trial of TP-03 to Treat Demodex Blepharitis and Secures $175 Million Credit Facility

02 Feb 2022 04:00:00 By Nasdaq GlobeNewswire

Tarsus Appoints Elizabeth Yeu, M.D., a Nationally Recognized Ophthalmologist and Eye Care Leader, to its Board of Directors

04 Jan 2022 06:00:01 By Nasdaq GlobeNewswire

Tarsus to Participate at Upcoming Virtual Investor Conferences

23 Nov 2021 13:30:00 By Nasdaq GlobeNewswire

Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

10 Nov 2021 13:30:00 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements

09 Nov 2021 13:05:02 By Nasdaq GlobeNewswire

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

04 Nov 2021 06:45:00 By Nasdaq GlobeNewswire

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

02 Nov 2021 14:00:00 By Nasdaq GlobeNewswire